Table 3 Demonstration of CHIKV IgG in CSF of Neuro-CHIKV and Non-CHIKV group by ELISA method.
Study Subjects | Positivity for IgG (%) | Negativity for IgG (%) |
|---|---|---|
Neuro-CHIKV patients (n = 46) | 29 (63%) | 17 (37%) |
Confirmed (n = 9) | 5 (56%) | 4 (44%) |
   Encephalitis (n = 4) | 1 (25%) | 3 (75%) |
   Myelopathy (n = 2) | 1 (50%) | 1 (50%) |
   Myeloneuropathy (n = 1) | 1 (100%) | 0 |
   Peripheral Neuropathy (n = 1) | 1 (100%) | 0 |
   Myopathy (n = 1) | 1 (100%) | 0 |
Suspected (n = 37) | 24 (65%) | 13 (35%) |
   Encephalitis (n = 20) | 15 (75%) | 5 (25%) |
   Myelopathy (n = 5) | 4 (80%) | 1 (20%) |
   Myeloneuropathy (n = 6) | 1 (17%) | 5 (83%) |
   Peripheral Neuropathy (n = 6) | 4 (67%) | 2 (33%) |
Non-CHIKV patients (n = 15) | 8 (53%) | 7 (47%) |